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The Bowling Green Study of the Primary and Secondary Prevention of
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WILLIAM E. FEEMAN, JR., 640 South Wintergarden Road, Bowling Green, OH 43402
ABSTRACT. The Bowling Green Study (BGS) is a 16 year ongoing study of the primary and secondary prevention
of atherosclerotic disease (ASD). This paper provides a descriptive analysis of the study, discusses the
evolution of the cholesterol retention fraction (a new lipid predictor), and presents a series of tables showing
the physical and metabolic characteristics of those patients who developed clinical atherosclerotic disease
during the first 16 years of the study.
The BGS has evolved a predictor of the lipid portion of ASD risk superior to those previously used. This
predictor, termed the cholesterol retention fraction (CRF), estimates the cholesterol entering the arterial wall
and thus promoting the ASD process as well as the cholesterol being removed from the arterial wall and thus
counteracting the ASD process. The BGS demonstrates that it is the balance between these two factors that is
crucial to the ASD process; it is the relative excess of cholesterol entering the artery wall compared to the
relative paucity of cholesterol being removed from the artery wall that promotes ASD and reversal of ASD
depends on reversing this process, such that more cholesterol exits the artery wall than enters it.
The basic ASD process is accelerated by cigarette smoking, a risk factor that is capable of producing clinical
ASD in the absence of cholesterol imbalance. Indeed, the BGS data reveal that cigarette smoking counteracts
the anti-ASD advantage conferred by low CRF. This advantage is also compromised by hypertension but,
whereas cigarette smoking exerts its effects in younger people, hypertension exerts its effects in older people
(who are less likely to smoke).
The three risk factors (CRF, smoking, hypertension) have been combined by the BGS into an instrument
that allows with high accuracy the prediction of the population at-risk for ASD at a single pass. This instrument
is termed the BGS Graphs, which not only identify the at-risk population but also guide therapy to reverse the
ASD process. The CRF portion of the BGS Graphs has been validated against 15 international studies that have
assessed the progression or regression of ASD in response to therapeutic intervention.
Finally, recommendations have been made, based on BGS findings, as to the use of lipid-reducing
medications to reverse ASD. In addition, recommendations have been offered concerning the treatment of
hypertension utilizing the BGS Graphs to guide antihypertensive therapy such that lipids are not adversely
affected while high blood pressure is being lowered. These recommendations are applied to the BGS Graphs
to demonstrate how the risk of future ASD may be minimized.
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INTRODUCTION
According to the American Heart Association,
atherosclerotic disease (ASD) is the leading cause of death
of adult Americans, killing 978,500 people in 1986, the
latest year for which such data are available (Heart Facts
1988). Of these deaths 524,100 were caused by heart
attacks and 147,800 were the result of strokes. The chief
causes of ASD are well known and consist of blood
cholesterol, cigarette smoking, and hypertension (Criqui
1986, Fraelecher 1973, Levy 1984, Oliver 1973).
Theoretically, if the causes of ASD are well known, then
correction of the underlying etiologies should lead to the
primary and secondary prevention of ASD. Indeed, it is the
opinion of at least one physician-worker in the field that
"in theory and principle, the problem of the disease
atherosclerosis has been solved" (Samuel 1986). The
purpose of the present paper is to provide a descriptive
analysis and the results of a study whose goal is the
primary and secondary prevention of ASD.
'Manuscript received 23 May 1991 and in revised form 16 September
1992 (#91-08).
MATERIALS AND METHODS
Study Site
The Bowling Green Study (BGS) is an ongoing
investigation of the primary and secondary prevention of
ASD. The BGS began in November 1974 and at the time
of submission of this paper was over 16 years old. The
patient population consisted of a private practice of family
medicine in Bowling Green, OH. The patient population
as of 1 January 1991 numbered 8,606 people of which
4,144 were men and 4,462 were women. These patients
ranged in age from newborns to nonagenarians (Table 1).
Since the BGS is ongoing, new patients are being added
to the study each year.
Bowling Green is a small college town in northwest
Ohio, about 20 miles south of Toledo. It is the county seat
of Wood County, and in 1990 had a population of about
12,000 people (1990 census). The students of Bowling
Green State University added an additional 16,000 to the
populace, and virtually all of these people received
medical care from the Bowling Green medical community.
Bowling Green was likewise the main source of medical
services for the rest of the residents of Wood County, an
additional 85,000 people. The populace was virtually all
Caucasian, the chief minority being Mexican-Americans.
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TABLE 1
Patient population demographics, by age groups.
"Age group" is determined by age at initial presentation
to the Bowling Green Study (BGS) in the
4 November 1974- 1 January 1991 time frame.
AGE GROUP (Years) MALE FEMALE TOTAL
0-9
10-19
20-29
30-39
40-49
50-59
60-69
70-79
80-89
90
TOTAL
462
830
1,536
606
283
196
130
71
28
2
468
849
1,588
590
302
239
145
104
48
9
950
1,679
3,224
1,196
585
435
275
175
76
11
4,144 4,462 8,606
Asian-Americans and African-Americans were also
represented, though only in small numbers.
Virtually all patients were free-living in the community.
Most were employed by the university or by numerous
small industries located within the town. Many of those
patients living outside the town were engaged in agriculture.
Patient Measures
Almost all patient data were taken from outpatient
visits. Each time a patient presented for medical care a full
set of vital signs were taken by the office nursing personnel.
These vital signs included blood pressure (BP), pulse,
respiratory rate, height, and weight. The BP was measured
in the sitting position, usually in the right arm. Diastolic BP
was measured in the fifth phase. Lipid data were obtained
from patients who had fasted 12-14 hours, and included
total cholesterol (CT), low-density lipoprotein cholesterol
(LDL), high-density lipoprotein cholesterol (HDL), and
triglycerides (TG). Occasionally, CT and HDL were
determined in patients who were not fasting. Glucose
tolerance data were determined in the fasting state and
two hours postprandial. The latter test was determined
precisely two hours after ingestion of the standard breakfast,
which consisted of one glass of orange juice, one bowl of
cereal with milk and sugar, and three pieces of toast with
butter and jelly. This meal consisted of 100 g of carbohydrate
and was consumed within a 15 min time span.
All laboratory data were collected and measured by the
same regional laboratory, based in Toledo, OH, using the
Technicon AutoAnalyzer (1975-1985) or the RA 1000
(1985 to present). The Technicon AutoAnalyzer used the
cholesterol esterase method as described in the Technicon
Method No. SM4-0139J86 of September 1986, as did the RA
1000. The HDL fraction was measured as supernatant
cholesterol after phosphotungstic acid precipitation.
Triglycerides were measured by the enzymatic blank,
corrected, as described in the Technicon Method No. SM4-
0173G90 of July 1990. The LDL fraction was calculated by
the standard Frederickson formula:
LDL = C_ - HDL - TG/5,
where TG were less than 500 mg/dl. Plasma glucose was
measured by the glucose oxidase reaction (Trinder method).
Quality control was done on a daily and weekly basis.
Calibration was done by CDC standard. Because LDL and
HDL data were not available to the BGS until January of
1978, lipid data obtained prior to this date were limited to
CT and TG.
The BGS used the body mass index (BMI) as its measure
of obesity. The BMI was calculated by the formula:
BMI = Weight (kg) / [Height (m)]2.
Follow-up on these patients was provided by direct
continuous patient care and by follow-up interviews in
hospital, by telephone interviews, or by review of medical
records. Full follow-up is not available on all 8,606
patients. Therefore, some cases of ASD may have escaped
BGS detection. This is regrettable, but unavoidable, in a
study of this nature. In any event, all patients known to
have suffered some form of ASD were included in this
paper (Tables 2-5).
TABLE 2
Distribution of Bowling Green Study (BGS) patients with
atherosclerotic disease (ASD) of the heart (ASHD), brain (ASBD),
and peripheral vasculature (ASVD), during the
4 November 1974- 1 January 1991 time frame.
ASD TYPE
ASHD
ASBD
ASVD
ALL ASD
TOTAL BGS Population
MALE
165 (4.0%)
60 (1.4%)
39 (0.9%)
196 (4.6%)*
4,144
FEMALE
168 (3.8%)
55 (1.2%)
24 (0.5%)
195 (4.3%)*
4,462
Numbers in parentheses indicate prevalence rate.
*Some patients had multiple system disease
Lipid Predictions
When this study began in 1974, the BGS followed the
guidelines of the Framingham Study, using CT and TG as
its lipid predictors (Kannel et al. 1971). In the BGS
experience, however, CT was only of value in predicting
subsequent ASD when CT exceeded 250 mg/dl and TG
was not of value in predicting future ASD.
The landmark paper by Miller and Miller (1975) re-
established the role of HDL in ASD when CT levels were
normal; LDL was found to be that portion of cholesterol
entering the artery wall, whereas HDL was found to be that
portion of cholesterol being removed from the artery wall.
ASD could thus be described as the result of an "overload"
of cholesterol entering the artery wall (LDL excess) or to
a deficiency in the cholesterol-removal mechanism (HDL
deficiency). Hence, when LDL and HDL levels became
available to the BGS in 1978, they were used as lipid
predictors. (Patients whose lipid data was obtained prior
to 1978 had only CT and TG measured.) Subsequently,
some patients with high HDL developed ASD as did some
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TABU- 3
Distribution of patients with atherosclerotic heart disease (ASHD) as to presenting ASHD manifestation during the
4 November 1974— 1 January 1991 time frame.
SEX
Male
Female
165
168
AMI
45
(27%)
19
(11%)
AP
23
(14%)
45
(27%)
ASHD
HX
72
(44%)
60
(30%0
AC1
5
(3%)
3
(2%)
CHF
13
(8%)
35
(21%)
TRE AI )MILL/ANGIOGRAM
POSITIVE
7
(4%)
5
(3%))
Numbers in parentheses indicate the percentage of patients with each manifestation.
Abbreviations are as follows: AMI = acute myocardial infarction, AP = angina pectoris, HX ASHD = history of ASHD, ACI = acute coronary insufficiency,
CHF = congestive heart failure. All terms are defined fully in Appendix I.
TABLE 4
Distribution of patients with atherosclerotic brain disease
(ASBD) as to presenting ASBD manifestation during
4 November 1974- 1 January 1991 time frame.
SEX HCVA TCVA TIA ASBD
HX
ACS
Male
Female
60
55 2
(4%)
13 9 24 14
(22%) (15%) (40%) (23%)
18 18 19 5
(33%) (20%) (35%) (9%)
Numbers in parentheses indicate percentage of patients with each
manifestation.
Abbreviations are as follows: HCVA = hemorrhagic cerebrovascular
accident, TCVA = thrombotic cerebrovascular accident, TIA = transient
ischemic attack, HX ASBD = history of ASBD, ACS = asymptomatic
carotid stenosis. All terms are defined fully in Appendix I.
TABLE 5
Distribution of patients with atherosclerotic vascular disease
(ASVD) as to presenting ASVD manifestation during
4 November 1974- 1 January 1991 time frame.
SEX
Male
Female
39
24
TAA
2
(5%)
—
AAA
14
(36%)
2
(8%)
ASPVD
19
(49%)
20
(83%)
ASVD
HX
4
(10%)
2
(8%)
Numbers in parentheses indicate percentage of patients with each
manifestation.
Abbreviations are as follows: TAA = thoracic aortic aneurysm, AAA =
abdominal aortic aneurysm, ASPVD = atherosclerotic peripheral vascu-
lar disease, HX ASVD = history of ASVD. All terms are defined fully in
Appendix I.
patients with low levels of LDL. Investigation of these
patients revealed that those with high levels of HDL also
had very high levels of LDL, and that those with low levels
of LDL also had very low levels of HDL. The BGS therefore
adopted the LDL:HDL ratio as its lipid predictor. However,
the LDL:HDL ratio did not prove to be the best lipid
predictor. A new lipid predictor was designed to reflect the
balance between incoming LDL cholesterol and the HDL
cholesterol being removed, the difference representing the
cholesterol remaining in the arterial wall. Thus the concept
of the Cholesterol Retention Fraction (CRF) was devised:
LDL - HDL.
LDL
The CRF represents the best available approximation of
the cholesterol accumulating within the artery wall,
expressed as a percentage of the incoming LDL.
Inspection of the BGS age-sex register of ASD patients
(Appendix I, Tables 6-11) reveals that HDL cannot compensate
for excess LDL. When LDL levels exceed 170 mg/dl (4.4
mmoles/L), even high levels of HDL do not afford protection.
Thus the CRF is abnormal at levels of 0.70 or higher, or at any
level if LDL >170 mg/dl. These two conditions define the
Cholesterol Threshold (C Thr), above which the patient is at
risk for the lipid portion of ASD risk.
Drug Intervention
The BGS therapeutic approach to patients who exceed
the C Thr is initially a combination of diet and/or exercise.
Such an approach often does not succeed in reducing the
CRF/LDL below the C Thr. After a trial of a minimum of one
month of nonpharmacologic therapy, hypolipidemic
medications are routinely employed to bring the CRF/LDL
below the C Thr. In cases where the C Thr is markedly
elevated, appropriate medications are begun initially along
with diet and exercise.
RESULTS
BGS Graphs
The BGS developed a screening tool that accurately
identified those people with a high probability of developing
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clinical ASD within the first eight decades of life. This tool,
known as the BGS Diagnostic and Therapeutic Graphs
(BGS Graphs), also provided the treating physician with
a guide to treatment of the leading causes of ASD. In
devising this tool, several combinations of risk factors
were examined for predictive ability, but only one
combination showed any relationship that allowed
prediction: the combination of the CRF, cigarette smoking
habit, and systolic blood pressure (SBP), the three main
ASD risk factors. A clear-cut relationship was apparent
when the CRF was plotted versus the SBP in never-
smokers (Fig. la), ex-smokers (Fig. lb), and current
smokers (Fig. lc) for patients aged less than 80 years. For
the purpose of plotting values the CRF was placed on the
ordinate and the SBP on the abscissa.
In each figure a mainstream of sequence of ASD
patients was detected, as well as a zone in which there
were few if any plots. The area of the graph in which most
plots fell defined the "danger zone," and the zone in which
few plots fell defined the "minimum risk zone." While the
minimum risk zone increased in size as one progressed
from smokers (Fig. lc) to ex-smokers (Fig. lb) to never-
smokers (Fig. la), only in the latter graph was the
distinction sufficiently clear-cut to permit precise definition
of the two zones by a line termed the ASD Threshold Line.
However, the benefits of having the patient stop smoking
were obvious—i.e., a bigger minimum risk zone occurred
in past-smokers (Fig. lb) than in current smokers (Fig. lc).
The vast majority of patient plots (Fig. la) fell above the
threshold line. Of the 64 plots on the graph, only 10 (16%)
fell below the line (Appendix II) and, of those 10 points,
only three were without extenuating circumstances. With
the "exception" of these cases, no patient whose plot was
initially within the minimum risk zone and remained
within the minimum risk zone during the study period
developed any form of clinical ASD to date.
Nineteen plots fell close to the threshold line. Four were
men aged 72-79 years; and three have died. The other
three male plots were those of a 67 year-old man, a 44
year-old man with a positive treadmill test, and a 55 year-
old man who died suddenly. Of the 12 female plots, three
involved cases in which LDL levels exceeded 170 mg/dl
cut-off, above which HDL is no longer able to compensate
for LDL. Of the other nine plots, one involved a 74 year-
old woman who had much higher lipids in the past in
association with a severe untreated hypothyroid condition.
The thyroid abnormality was corrected, and her plot
represented her lipids after she achieved the euthyroid state.
The other female plots mainly represented women in their
seventies. Only three of the twelve women have died.
The value of the BGS Graphs in guiding therapy has
been demonstrated by evidence that only one asymptomatic
patient initially in the danger zone suffered subsequent
clinical ASD after being brought into the minimum risk
zone and maintained there for a minimum of two years.
The one exception was a 62 year-old woman who had a
previous history of hypertension, but had discontinued
her medication prior to her initial visit. Initial blood
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FIGURE 1. Relationship between cholesterol retention fraction (CRF) and systolic blood pressure (SBP) in subjects who suffered any form of clinical
atherosclerotic disease (ASD), from 4 November 1974 - 1 January 1991- a) Subjects who had never smoked cigarettes, b) Smokers who had stopped
using cigarettes at least six month prior to the initial ASD event, c) Current smokers, or subjects who had stopped using cigarettes less than six month
prior to ASD.
*Female subjects.
+Male subjects.
"Male subjects in a) who used alternate tobacco products (chewing tobacco, pipe, cigar).
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pressure and lipid chemistry in 1975 placed her deep in the
danger zone and intervention was instituted to place her
in the minimum risk zone. After ten years of treatment, she
was found to have a severe asymptomatic carotid stenosis,
which was surgically removed and has not recurred. She
also developed a mild case of angina pectoris, which
resolved on aspirin therapy.
Changes in CT might also predict ASD resolution.
However, CT was not a good predictor of the cholesterol
portion of ASD risk (Figs. 2, 3). Distribution curves
comparing CT values in people with and without ASD for
both male (Fig. 2a) and female (Fig. 2b) patients were
biphasic, with a peak at lower CT levels and another peak
at higher CT levels. The lower peak represented HDL
disease whereas the higher peak represented LDL disease.
Curves for the age at ASD onset in men and women, as a
function of CT, were likewise not continuous, but rather
appeared to represent two distinct populations, one for
LDL disease and one for HDL disease (Fig. 3). Moreover,
the "uppermost" end of each curve portion began at about
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the same age, indicating that LDL disease and HDL disease
are almost equipotent in causing ASD. Whereas LDL
abnormalities could be detected by CT screening, HDL
abnormalities would be missed since low levels of HDL do
not result in high levels of C r
These graphic representations (Figs. 2, 3) were based
on CT alone and did not take into account cigarette
smoking. The pertinence of stratifying cholesterol risk in
terms of cigarette smoking was ascertained (Fig. 4a,b).
This approach demonstrated that in the absence of
cigarette smoking, there was a direct relationship between
the CRF and the age at ASD onset, whereas cigarette
smoking eliminated the relationship. The relation between
CRF and smoking for ex-smokers was intermediate.
However, examination of this relationship in terms of CT
revealed that even in the absence of cigarette smoking, CT
did not provide a smooth predictor of ASD risk (Fig. 5a,b).
A graph constructed using CT on the ordinate and SBP on
the abscissa showed no predictive pattern, and indeed
resembled a random scattering of plots.
Dyslipidemia and Hypertension
The link between dyslipidemia (DLP) and hypertension
(HT) has been examined in the present study. Since 1974,
the BGS has evaluated 177 men and women who were
found to have incidental HT. It has been the policy of this
study that all patients over one year old will have BP taken
at each office visit, regardless of the nature of the
presenting complaint. If SBP was 140 mm HG or higher,
the patient was asked to return weekly for four weeks to
have his/her BP taken. If the BP remained high on these
repeat measurements, lipids were tested. To be eligible for
this substudy, the patient could have not had any other
compelling reason for lipid testing such as chest pain,
diabetes, a family history of ASD, a family history of DLP,
and so on.
From 1 January 1978 (when LDL and HDL testing
became available to the BGS) to 1 January 1991, the BGS
has accumulated complete lipid data on 67 men and 56
women with incidental HT. Of that population, 58% of
men and 47% of women had cholesterol abnormalities
exceeding C Thr (CRF > 0.70 or LDL > 170 mg/dl). An
additional four men (6%) and two women (3%) had
borderline CRF values of 0.68 or 0.69. Given this intimate
association between DLP and HT, it would appear to be
unwise for a treating physician to use antihypertensive
medications that adversely effect the lipids.
Evidence supporting this proposition can be found by
examining the average ages of ASD onset in terms of
dyslipidemic vs. normolipidemic hypertension. If one
ignores the cigarette-smoking status of ASD patients, then
of the 59 male and 65 female hypertensive ASD patients,
36 males (61%) and 31 females (48%) were dyslipidemic
(exceeded C Thr). The dyslipidemic hypertensive male
ASD patients had an average age of ASD onset of 66 years
and 39% have died. Comparatively, the 23 normolipidemic
120
Total Cholesterol
FIGURE 2. Frequency distribution or atnerosclerotic disease CASUJ as compared with total serum cholesterol (mg/dl) in male (a) and female (b) patients.
Light bars = Patients not known to have developed ASD.
Dark bars = Patients known to have developed ASD.
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FIGURE 3- Average age of initial atherosclerotic disease event relative to
total serum cholesterol cohort (mg/dl).
Light bars = Male patients.
Dark bars = Female patients.
hypertensive male ASD patients had an average age of
ASD onset of 68 years and 22% have died. The dyslipidemic
hypertensive female ASD patients had an average age of
ASD onset of 68 years and 29% have died. Comparatively,
the 34 normolipidemic hypertensive female ASD patients
had an average age of ASD onset of 75 years and 26% have
died. Thus, dyslipidemic hypertensive ASD patients have
their ASD occurring earlier in life and that ASD is more
likely to be fatal.
A pattern similar to that above was seen if only never-
smokers were examined. Such an analysis was limited by
relatively few male patients, since the BGS age-sex registry
revealed that most male ASD patients were current or
former cigarette smokers. Thus, there were only 19
hypertensive male ASD patients who never smoked
cigarettes. Of these 19 hypertensive patients, 14 were
dyslipidemic. The average age of ASD onset of these 14
dyslipidemic hypertensive male ASD patients was 71
years, as compared to 77 years for the 5 normolipidemic
hypertensive male ASD patients. There were 57
hypertensive female ASD patients who never smoked
cigarettes. Of these 57 patients, 27 were dyslipidemic. The
average age of ASD onset of these 27 dyslipidemic
hypertensive female patients was 72 years, compared to
77 years for the 30 normolipidemic hypertensive female
ASD patients.
DISCUSSION
The BGS Graphs (Fig. la-c) are useful tools for
defining at-risk population for ASD and for guiding
therapy of major ASD risk factors. The BGS Graphs
clearly demonstrate the advantages of smoking
discontinuation. The size of the minimum risk zone
increases by orders of magnitude by the simple expedient
of stopping smoking (Fig. lc vs. lb).
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FIGURE 4. Average age of initial atherosclerotic disease (ASD) event
relative to cholesterol retention fraction (CRF) cohort in men (a) and
women (b) with different cigarette smoking status.
Open bars = Non-smokers.
Light bars - Past smokers.
Dark bars = Current smokers.
Treatment of Hypertension
The BGS Graphs suggest that the manner in which the
attending physician treats hypertension is of importance.
If a patient is in the danger zone solely because of elevated
SBP, then lowering SBP using a medication that adversely
effects the CRF simply shifts the patients' plot from the
higher SBP-lower CRF end of the danger zone to the lower
SBP-higher CRF end. In such an instance, the plot never
leaves the danger zone, but rather simply shifts from one
end to another. This is not a benign effect. Younger
patients display ASD characteristics by higher CRF and
lower SBP whereas ASD in older patients is characterized
by lower CRF and higher SBP. Use of antihypertensive
medication with adverse lipid effects may accelerate the
ASD process. This assertion is speculative, but the failure
of the Multiple Risk Factor Intervention Trial study to
reduce mortality in the special care groups may be related
to the use of diuretic therapy, the adverse effects of which
may have prevented the anticipated drop in CT that should
have resulted with the low-cholesterol diet given to all
study members (Cohen 1982).
Specifically, diuretics have been shown to raise LDL
and in some cases to lower HDL (Ames 1986, Gleuck 1985,
Hegeland et al. 1978, Lucas 1986, McKenney et al. 1986,
Morin 1984). Only two diuretics do not have this untoward
effect—indapamide (Meyer-Sabellak et al. 1985, Osei et al.
1986) and spironalactone (Lucas 1986). On the other hand,
beta-blockers without ISA—i.e., propanolol, atenolol,
metoprolol, etc.—have been shown to lower HDL
(Hegeland et al. 1978, Hooper et al. 1981, Leren et al. 1980,
Samuel et al. 1986). However, beta-blockers with ISA—
i.e., pindolol, acebutolol, and labetolol—have been shown
to have neutral or (in case of pindolol) beneficial effects
on HDL (Gleuck 1985, Samuel et al. 1986).
Most of the other antihypertensive agents have neutral
effects on the lipids, leaving a wide variety of choices for
the treating physician. Indeed, a newly released peripheral
alpha blocker, doxazosin, appears to raise HDL and lower
LDL (Pool 1991), making it a first line drug in dyslipidemic
HT. This study shows that proper treatment of HT requires
that the treating physician know his/her patient's lipid
status and utilize medications that favorably effect lipids,
or are at least lipid neutral, in all cases of dyslipidemic HT.
Optimal Therapy of Dyslipidemia
The BGS Graphs also point the way toward the optimal
therapy of dyslipidemia. The goal of dyslipidemic therapy
is to lower LDL and/or raise HDL such that the CRF-SBP
plot is lowered below the ASD threshold line. As noted in
the Results section of this paper, when a person's plot is
lowered into the minimum risk zone prior to the onset of
clinical ASD, and is maintained there for a minimum of two
years, then with one exception, no such person has
developed clinical ASD. The patient who did develop ASD
despite therapy that moved her plot into the minimum risk
zone was 73 years old at the time of ASD onset, has
suffered no major sequela except a carotid endarterectomy,
and continues to lead an active life at 79 years of age.
The results of 15 international trials are presented
(Appendix III). These trials can be stratified in terms of the
CRF achieved during the trial and the consequent effect on
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FIGURE 5. Average age of initial atherosclerotic disease (ASD) event
relative to total serum cholesterol (CT, mg/dl) cohort in men (a) and
women (b) with different cigarette smoking status.
Open bars = Non-smokers.
Light bars = Past smokers.
Dark bars = Current smokers.
ASD (Fig. 6). It will be noted that the better the improvement
in the CRF, the more likely ASD is to regress in follow-up
evaluation. It is also true the better the improvement in the
CRF, the faster plaque resolution occurs. The evidence for
this proposition lies in the fact that in the LRC (Lipid
Research Clinics 1984), in the HSS (Frick et al. 1987), and
in the Buchwald group (Buchwald et al. 1990), improvement
in subsequent ASHD morbidity in the treatment group was
not evident until the third year of the study. However, in
the Brown III group (Brown et al. 1990), angiographic
regression was seen within 2.5 years and in the Blankenhorn
study (Blankenhorn et al. 1987) significant plaque regression
was noted within two years. The difference in time frame
relates directly to the reduction in CRF obtained by the
studies: 73% for the LRC, 71% for the HSS, 63% in the
Buchwald group, 57% in the Brown III, and 37% for the
Blankenhorn study. In addition, the LRC (CRF = 73%)
reduced subsequent coronary events by 19% whereas
the HSS (CRF = 71%) reduced subsequent coronary
events by 34%.
Hypolipidemic Therapy
Once the C Thr is determined to be abnormal, the
physician next determines which portion of the C Thr is
responsible. In the BGS, the highest acceptable LDL is
169 mg/dl (4.4 mmoles/L) and the lowest acceptable HDL
is 40 mg/dl (1.0 mmole/L). It should be noted that different
laboratories use different techniques to measure the
various lipid fractions; hence, the upper and lower limits
of normal for these fractions will vary from lab to lab. The
values presented here represent those values obtained by
the BGS regional reference lab in Toledo, OH, and should
be used by physicians active in the fight against ASD as
guidelines until such time individual physicians can establish
their own guidelines by examining their own patient
population. Such "new" guidelines should not differ much
from the BGS standards.
If the LDL is at fault or predominantly at fault, a
therapeutic regimen aimed at reducing LDL should be
initiated. Such a regimen begins with a diet low in
saturated fat and cholesterol. If obesity is present, weight
loss is recommended. In the experience of the BGS, diet
is often not effective in reducing LDL to the requisite
169 mg/dl or less. At this point a LDL drug should be used
(Table 12). The BGS experience with the various LDL
drugs is discussed (Appendix IV).
On the other hand, if the CRF is abnormal because of
HDL, then an HDL regimen is used. Such a regimen cannot
include an LDL diet unless LDL is also elevated because a
low cholesterol, low saturated fat diet is also a cause of low
HDL levels (Miettenen 1982). Indeed, the philosophy of
the present study is to correct an HDL defect if such exists
rather than to use an LDL regimen where no disorder of
LDL is evident. The initial step, then, is to do those things
that are known to elevate HDL. The BGS first prescribes
an exercise program (Eder 1981) and, if no personal or
family history of alcoholism is present, a minimal intake of
ethanol of one ounce per day (Criqui 1986) is prescribed.
If obesity is present, weight control is advised (Hartung
1983). Smoking is always proscribed as it accelerates the
course of ASD, especially in patients with low HDL (BGS
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unpublished data). If patients are unwilling or unable to
comply with this regimen, then an HDL drug is utilized
(Table 12, Appendix IV). The goal of this therapy is to raise
HDL such that the CRF is brought below 0.69. The BGS
experience with HDL drugs is discussed (Appendix IV).
Finally, if both LDL and HDL abnormalities are present,
a combined approach is used. Such a regimen includes low
saturated fat/cholesterol diet, exercise, weight loss, and
smoking cessation. If this regimen fails to bring the cholesterol
level below the C Thr, various combinations of LDL and HDL
medications are employed to achieve this goal.
The goal of these two regimens is to retard the ASD
process by correcting the lipid fraction responsible.
This is achieved by lowering LDL below 170 mg/dl
(4.4 mmoles/L) and raising HDL above 40 mg/dl
(1.0 mmole/L), such that the CRF is maintained below 70%
in patients free of clinical ASD, and below 60% in patients
with clinical ASD. The rationale for these goals is
demonstrated by the ASD plaque dynamics at various
levels of CRF (Fig. 6).
50%
40%
30%
— Kelsey
Brown III
-Fox
LRC. Hiermann
-Nikkiia
-Frick
Neitzel, Schuler
- Watts
-Buchwald
Lewis, Brown II
Duffield
—Bro
— Progression
— Stabilization
ampeau
—Blankenhorn
Regression
FIGURE 6. Comparison of cholesterol retention fraction (CRF) with results
noted during studies of atherosclerotic disease (ASD): regression,
stabilization, or progression of plaques. Names refer to authors of papers
reporting results. Size of "circle" enclosing the C in the CRF column
represents the amount of cholesterol remaining in the arterial wall.
CONCLUSIONS
The BGS has evolved a series of graphs (Fig. 1) that
define at a single pass the population at risk for ASD. These
graphs combine the three major risk factors for ASD: CRF,
cigarette smoking, and hypertension. By defining the
population at risk of ASD, the BGS Graphs simultaneously
define the population at minimal risk. Such a distinction
is important because it allows the attending physician to
treat those people who are at moderate or high risk of
ASD, while also allowing the people at minimum risk to
avoid unneeded medical treatment.
The BGS Graphs also guide the attending physician in
his/her attempt to reverse ASD, the leading disease killer
of the American populace. The aim of such therapy is to
modify the patient's risk factors such that the patient's plot
moves out of the moderate or high risk zones and into the
minimum risk zone. Such therapy mandates cessation of
cigarette smoking, manipulating the CRF by lowering LDL
and/or raising HDL (preferably both), and lowering SBP
in such a manner that the CRF is not adversely affected.
Such an approach has been utilized by the BGS, such that
there has been a marked reduction in ASD events in
treated patients.
The extent to which the CRF must be lowered depends
upon the associated SBP. It also depends upon whether
ASD reversal or stabilization is necessary. Data from 15
investigations of ASD reversal (Fig. 6) strongly suggest that
ASD stabilization occurs in the 0.60-0.69 range whereas
ASD reversal requires lowering the CRF to 0.59 or lower.
Several questions remain to be investigated. The left
upper corner of the minimum risk zone of the BGS Graph
for never-smokers (Fig. la) include CRF values greater
than 0.69- One could argue that in the face of very low SBP,
an elevated CRF may not require treatment, but at present
the BGS elects to treat all patients with CRF >0.70. Likewise
the right lower corner of the minimum risk zone of the
graph contains SBP values >14O mm HG. One could also
argue that in the face of low CRF, moderate hypertension
need not be treated, but at present the BGS elects to treat
all patients with SBP >14O mm HG. These areas of
uncertainty have too little data to be settled at present and
will need to await further research. In addition, the BGS
is currently investigating the roles of TG and diabetes in
ASD, as well as the antithrombotic effects of the combination
of omega-3 fatty acids with aspirin. These areas will be
reported in the future.
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APPENDIX I
Appendix I lists all BGS patients who developed some form of clinical
ASD from 4 November 1974 to 1 January 1991. As of 1 January 1991, 196
men and 195 women sustained some form of clinical ASD, giving a
prevalence rate of 4.8 per 100 men and 4.4 per 100 women. One hundred
sixty-five men and 167 women suffered some manifestation of ASD of
the heart (ASHD); 60 men and 55 women suffered some manifestation
of ASD of the cerebral circulation (ASBD); and 39 men and 24 women
suffered some manifestation of ASD of the peripheral vasculature
(ASVD). A description of the criteria used to diagnose each of the
individual ASD categories follows:
1) Acute Myocardial Infarction (AMI): Typical midsternal chest pain
described as a heavy weight/pressure sensation, as a gripping/
squeezing sensation, or sometimes as an ache, accompanied by
typical EKG and/or cardiac enzyme changes. Radiation to the left arm
or to the jaws, though often present, was not required for this
diagnosis.
2) Angina Pectoris (AP): Typical midsternal chest pain, usually
described as above, but not in an acute setting and not accompanied
by the typical EKG changes and/or enzyme changes. Such pain was
usually precipitated by exertion or emotion, and less commonly by
exposure to the cold or by eating. Treadmill tests were used to verify
the diagnosis; a positive test was required to make the diagnosis.
From time to time, an anginal equivalent symptom such as shortness
of breath or dizziness was accepted in lieu of chest pain, and in such
cases a positive treadmill test was also required to make this
diagnosis. Relief of pain with rest and/or nitroglycerin "was also
required to support the diagnosis.
3) Acute Coronary Insufficiency (ACI): Typical pain as described
above, in an acute setting, but without EKG and/or cardiac enzyme
changes. These patients were generally stabilized at Wood County
Hospital and transferred to Toledo for definitive care, which usually
meant coronary artery bypass graft surgery.
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4) History of ASHD (HX): This category includes various groups of
patients, but chiefly those who have had an EKG showing an old
AMI or those who have been diagnosed as having ASHD by a
physician licensed to practice medicine in the state of Ohio, or
occasionally in some other state. Where possible, the diagnosis was
verified by review of the medical records.
5) Congestive Heart Failure (CHF): Shortness of breath and limitation
of physical activity, accompanied by bilateral rales on auscultation
of the lungs and/ or compatible chest radiographs. A therapeutic
response to diuretics and digitalis "was required to confirm the
diagnosis.
6) Positive Treadmill/Coronary Angiogram: This category includes
those patients with atypical symptoms, which nonetheless suggested
ASHD, and in whom the treadmill test was read as positive by the
Wood County internists or cardiologists, or in whom the coronary
angiogram showed at least 50% luminal narrowing.
7) Hemorrhagic Stroke (CVA): One woman presented with acute
headache, nuchal rigidity, and blood in spinal fluid. Her aneurysm
was surgically treated in Toledo after stabilization in Wood County
Hospital. The other woman presented in coma and had a CAT scan,
which showed a hemorrhagic stroke.
8) Thrombotic Stroke (TCVA): Acute onset of unilateral weakness or
paralysis with or without accompanying paresthesis. These symptoms
could be definite or progressive; however, they had to persist over
a time. Progressive symptoms were treated with heparin and usually
resolved with protracted span of anticoagulation. Patients with
nonatherogenic sources of cerebral emboli, such as rheumatic heart
disease, were excluded from this category.
9) Transient Ischemic Attack (TIA): Symptoms as above, but of a
transient nature, resolving spontaneously within an hour.
10) Asymptomatic Carotid Stenosis (ACS): Findings of an asymptomatic
carotid bruit on routine physical examination with confirmation by
doppler. If the doppler suggested more than 50% stenosis,
angiographic studies were done to confirm the diagnosis, but for
more severe cases surgical confirmation was accepted.
11) History of ASBD (HX): Diagnosis of an ASBD event was made by
another physician licensed to practice medicine in the state of
Ohio, with confirmation by review of medical records "where
possible. Also accepted in this category were the patients with
CAT scans of the brain that showed old CVAs.
12) Thoracic Aortic Aneurysm (TAA): This diagnosis was made on chest
x-ray in one case and at autopsy on the other case.
13) Abdominal Aortic Aneurysm (AAA): Findings of a large pulsating
abdominal mass on examination of the abdomen, "with confirmation
by echo or CAT scan. AAA could also be an incidental finding on
radiographic evaluation of the abdomen.
14) ASD of the arteries below the level of the aorta (ASPVD): Findings
of cold, bluish feet usually without a palpable pulse on physical
exam or history of intermittent claudication. An incidental finding of
ASPVD during radiographic evaluation of other areas was also
accepted.
15) History of ASPVD (HX): Diagnosis was made by another physician
licensed to practice medicine in the state of Ohio; most patients had
been previously operated on for AAA.
In these tables, the "age" column refers to the age at onset of ASD in
ASHD, ASBD, or ASVD. The presence off" beside the age indicates that
the patient has expired. A" •" before the designation in the ASHD column
indicates that the patient has multisystem ASD. The "Op, HDL, LDL, CRF,
TG, and PSL" columns derive from screening tests done for many
reasons, one of which could be ASD; however, such data was often
obtained months to years prior to the actual onset of clinical ASD. The
"Cigarettes" column refers to the patient's status regarding smoking at the
time of his/her initial ASD event; a "+" means that he/she was smoking
at the ASD onset, whereas a "past" means that he/she had quit smoking
at least six months prior, and a "-" means that he/she never smoked
cigarettes. Some men had smoked pipes or cigars, or had chewed
tobacco, without ever having smoked a cigarette, and this is indicated
with the appropriate label. The column labeled "PSL" refers to the 2 hr
postprandial plasma sugar level. Where the data is not available, but
where the patient is know to be diabetic, a "D" is used to designate this
condition. A "D" is also used to designate a known diabetic whose PSL
value is less than 200 mg/dl; in such cases the actual test value obtained
has a "D" appended. The other physical parameters were obtained at the
time of the patient's first visit to the author's office, usually months to
years prior to the first clinical event. "IH" behind the datum means that
inhospital values were used. "RX" behind the datum means that the
parameter had already been treated by another physician. A "*" behind
one woman's lipids (Table 9) indicates that these were the values after
treatment of a severe untreated hypothyroid condition.
TABLE 6
Male ASHD.
Age ASHD HDL LDL CRF TG PSL Cigarettes SBP DBP BMI
24
33
34
35
36
39
42
42
42
AP
AMI
AMI
AMI
AMI
HX
AMI
AMI
HX
209
217
248
319
334
204
196IH
244
389
33
48
47
60
33
—
30IH
40
27
134
148
163
204
265
—
190IH
174
338
0.75
0.68
0.71
0.71
0.88
—
0.72
0.77
0.92
211
105
192
273
178
214
283IH
152
118
90
74
93
74
102
88
—
78
95
past
past
138
116
154
114
126
150
128
138
152RX
76
70
96
74
80
78
84
84
80RX
22
25
33
27
28
24
17
26
40
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Age
43
43
44
44
45
45
45t
45
45
45
46
46
46
46
47
47
47
48
48f
48
49
49
49
50t
50
50
51
51
52f
52
52
53
53
531
53
53
53t
54f
54t
ASHD
AMI
AP
ACI
+Treadmill
HX
AMI
•SLID
HX
AP
HX
AP
AMI
HX
AMI
HX
ACI
HX
AP
•HX
•HX
AMI
HX
AMI
•HX
•AP
HX
AMI
HX
•AP
ACI
HX
AMI
•AMI
HX
AP
HX
CHF
SUD
•AMI
CT
278
339IH
222
327
248
214
188
373
258
285
186
258
173
296
279
239RX
301
212
212
173IH
275.
—
257
213
318
274
—
157
304
194
—
220
247
—
216
216
193
212
270
HDL
36IH
25
56
—
26
34
—
32
36
—
—
47
41
32
25RX
35
—
35
54IH
—
—
71
43
39
66
—
44
—
30
—
—
—
—
34
33
48
—
_
LDL
—
—
220
—
140
92
—
168
210
—
—
115
201
200
173RX
196
—
138
92IH
—
—
142
154
232
195
—
90
—
138
—
—
—
—
166
162
118
—
CRF
—
—
0.75
—
0.81
0.63
—
0.81
0.83
—
—
0.59
0.80
0.84
0.86
0.82
—
0.75
0.41
—
—
0.50
0.72
0.83
0.66
—
0.51
—
0.78
—
—
—
—
0.80
0.80
0.59
—
_
TG
78
559IH
1168
256
250
242
310
118
288
195
264
168
70
272
235
206RX
351
278
197D
133IH
140
—
220
80
235
81
—
116
360
130
—
173
614
—
81
104
136
299
263
PSL
95
—
449
117
75
—
—
—
104
208
102
125
262
—
69
—
128
152
—
—
117
—
290
80
95
—
—
132
181
93
—
122
607
—
108
103
127
101
136D
Cigarettes
_
+
+
-
+
+
+
+
-
past
past
+
+
-
past
+
past
+
+
+
+
+
past pipe
+
+
+
+
+
+
+
past
+
past
+
+
-
+
+
+
SBP
178
166
130
120RX
124
130
128
166
124
132
210
132
148
136
162
136
160
168
132RX
94
140
168
132RX
130
110
194
124
148RX
190
144
126RX
152
118
168
124
152
120
150
162
DBP
84
80
80
88RX
60
88
78
104
86
76
120
74
84
90
108
84
98
84
72RX
66
68
94
86RX
76
80
106
90
98RX
104
80
90RX
90
78
98
90
90
92
94
90
BMI
20
28
29
38
24
26
27
22
34
27
37
26
27
—
22
37
28
29
28
15
24
30
35
19
27
21
—
42
39
30
—
24
29
30
24
26
22
33
31
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54
55
55t
56
56
56
57
57
57
57
57
58
58
58
58
59
59t
59
59t
60f
60f
60
60
60
60
61
61
62
62
62f
63t
631
63
63t
63t
63
64
64f
64f
AMI
•AP
SUD
•AP
AMI
•HX
AMI
+Treadmill
AP
HX
AMI
ACI
AMI
•HX
CHF
HX
CHF
AP
SUD
AMI
•AP
HX
AMI
HX
HX
AMI
HX
AP
+Treadmill
HX
•AMI
•AMI
HX
+ANGIOGRAM
•HX
+Treadmill
•ACI
•CHF
AMI
193
192
269
246
230
—
213
—
188
200
282
153
245
244
—
206
235
256
—
200
173
249
240
203
192
387
224
226
235
—
261
214
183
212
—
324
240
356
216
34
40
51
50
64
36
58
36
31
31
34
48
51
24
40
48
59
30
38
44
136
153
162
107
111
148
222
159
167
173
142
89
307
159
139
116
126
237
160
154
0.75
—
0.74
0.69
116
124
381
167
206
0.53 278
0.42
0.76
0.74
—
0.77
—
—
0.81
—
—
—
0.82
—
0.76
0.46
0.83
0.85
—
0.71
—
—
0.59
0.53
0.87
0.76
—
0.71
77
82
200
276
252
193
161
185
258
166
93
225
155
136
277
184
207
198
278
105
150
97
136
284
212
278
91
226
78
99
99
113
100
125
114
225
past
184
127
124
—
415
94
64
144
110
93
162D
111
155
89
114
117
100
198
127
115
93
114
+
past
+
past
past
past
+
+
-
+
pipe
past
pipe
+
+
past
+
+
past
pipe
past
past
past
past
140
154
122
148
132
142
180
128
158
148
110
158
150
160RX
136
140
136
142RX
122
184
162RX
138
164
160
142
136
142
204
126
128RX
158
154
152
120RX
148
142
140
180
198
90
94
78
92
98
100
100
80
100
80
70
104
94
92RX
78
72
74
110RX
82
120
84RX
74
96
98
88
80
88
110
78
80RX
90
84
92
82RX
102
64
70
100
100
27
33
30
26
24
22
28
25
28
29
32
35
29
34
24
23
29
31
25
31
24
24
33
36
24
28
26
40
24
28
27
28
19
30
—
30
25
27
_
Age ASHD CT
65
65+
66
66
66t
66f
66f
66f
66
67
67+
67
67
68
68f
68
68
68f
68
69t
69t
69t
69
69
70t
70
70
70f
70t
70
71t
71
71
71t
71t
72
72
72t
72+
AMI
•HX
AMI
•AP
•HX
•HX
AMI
•SUD
•HX
HX
AMI
HX
HX
AMI
•AMI
AP
HX
HX
HX
HX
•AMI
•CHF
CHF
+Treadmill
HX
•HX
HX
HX
HX
•HX
AMI
HX
•HX
HX
HX
HX
+Treadmill
•HX
CHF
—
230
—
207
169IH
264
—
301
263
—
—
—
—
314
310
332
178
157IH
—
191
243
126
238
208
166
354RX
244IH
230
—
—
201
—
114IH
254
—
183
204
256
206
HDL
—
25
—
35
—
42
—
49
42
—
—
—
—
44
—
—
42
50IH
—
—
—
52
55
42
—
—
34IH
71
—
—
44
—
35IH
38
—
32
—
49
29
LDL
—
—
153
—
190
—
207
188
—
—
—
—
238
—
—
113
90IH
—
—
—
62
148
130
—
—
175IH
143
—
—
129
—
49IH
190
—
129
—
186
154
CRF
—
—
0.77
—
0.78
—
0.76
0.78
—
—
—
—
0.82
—
—
0.63
0.44IH
—
—
—
0.16
0.63
0.68
—
—
0.81
0.50
—
—
0.66
—
0.29IH
0.80
—
0.75
—
0.74
0.81
TG PSL
—
917
—
93
—
160
—
223
163
—
—
—
—
160
126
1014
117
87IH
—
128
225
61
176
180
125
278RX
176IH
79
—
—
138
—
151IH
131
—
I l l
288
103
113
—
388
—
107
—
103
—
112
125
—
—
—
—
151
108
181
—
—
—
82
87
89
217
164
121
90
—
—
168
—
108
—
—
—
—
92
94
—
_
Cigarettes
past
past
-
-
+
+
past
+
past
past
past
-
-
past
+
+
past
+
past
+
+
+
past
past
past
past
past
-
-
past
past
past
-
past
+
+
past
+
_
SBP
138
168
130
104
188
190
130
166
186RX
160
190RX
94
136
158
168
152RX
182
86
144RX
146
138
108
150RX
150
150
122
124
110
130RX
130RX
152RX
160
160RX
144RX
128
122
142
174
108
DBP
66
106
84
48
100
98
96
104
42RX
88
80RX
66
80
78
88
84RX
100
44
80RX
96
82
60
70RX
74
90
80
80
62
90RX
70RX
90RX
90
84RX
76RX
80
70
80
78
70
BMI
23
37
21
30
28
31
—
26
23
25
34
26
29
27
26
28
41
17
36
25
20
24
34
32
25
26
27
19
29
32
26
32
—
24
16
22
28
29
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TABLE 6 (Continued)
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TABLE 6 (Continued)
Age
73t
73t
73
73t
73t
74 |
74
74
74
75
76
76f
76 |
76f
77
78f
78
79
79t
79
79t
79
81f
81t
81t
81t
82f
82f
83t
83t
84
84f
84f
85t
85t
86
87
87t
90f
ASHD
•HX
•AP
•HX
•AMI
•HX
•CHF
HX
•HX
AP
HX
•AP
HX
•HX
•AP
HX
•HX
•HX
•HX
CHF
HX
HX
•AMI
AMI
•HX
•CHF
•HX
•HX
HX
•CHF
SUD
•AP
•AP
HX
AMI
HX
CHF
CHF
•HX
•AP
CT
283
263
212
163
168RX
264
292
184IH
227
288RX
151IH
208
242IH
252
181
271
270
117
—
226
—
178RX
176
19HH
236IH
229
302
244
200
—
241
232
278
202
190
185
180IH
280
248
HDL
40
38
47
32
41RX
41
47
25IH
46
118RX
31IH
36
34IH
47
80
44
33
34
—
44
—
37RX
—
25IH
27IH
70
58
—
34
—
—
49
59
—
31
58
—
—
48
LDL
160
196
136
94
73RX
175
222
110IH
167
157RX
88IH
135
136IH
171
88
201
194
73
—
164
—
124RX
—
94IH
166IH
137
202
—
157
—
—
154
193
—
113
107
—
—
182
CRF
0.75
0.81
0.66
0.66
0.44
0.77
0.79
0.77
0.72
0.25
0.65
0.73
0.75
0.73
0.10
0.78
0.83
0.53
—
0.73
—
0.70
—
0.73
0.84
0.49
0.71
—
0.78
—
—
0.68
0.69
—
0.73
0.46
—
—
0.74
TG
407
146
137
183
270RX
241
116
244IH
71
67RX
177IH
184
36OIH
169
66
130
216
52
—
115
—
86RX
91
362IH
214IH
108
207
113
47
—
172
146
132
100
232
98
93IH
196
91
PSL
403
133
102
326
—
140
97
—
94
—
—
115
—
198
94
—
266
91
—
153
—
—
269
—
—
79
299
116
—
—
119
170
80
—
—
—
169IH
342
146
Cigarettes
cigars
past
past
chews
past
pipe
-
pipe
-
-
past
past chews
+
past
past
past
chews
past cigars
cigars
past
-
past cigars
+
-
chews
past
past
-
pipe
past
chews
past
past
-
past
past
-
past
-
SBP
162
144
168RX
150RX
112RX
220
164
132
152RX
120
160RX
124
128RX
140
148
186
146
146
118
144
140RX
110RX
132
146
96
140
128
156
144
168
152
170
122
146
160
144
184
200
138
DBP
104
76
100RX
80RX
78RX
108
100
76
80RX
70
86RX
84
80RX
80
94
100
94
80
70
80
80RX
70RX
78
66
54
76
72
88
80
80
92
94
64
80
84
80
92
100
70
BMI
30
29
27
32
27
28
25
33
30
22
24
26
34
—
27
28
30
25
22
24
—
22
25
26
27
16
23
26
24
25
24
21
22
21
25
30
26
25
26
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TABLK 7
MaleASBD.
Age ASBD HDL LDL CRF TG PSL Cigarettes SBP DBP BMI
45f
48
50t
50
53
55
56
56t
56
57t
57
58
59t
6lt
62
64f
65
65
66
66
66
67
68f
68f
69t
69
69
70
70f
70
70
71
72f
72f
75
731
73t
73t
•HX
•HX
•ACS
•TIA
ACS
HX
•HX
TCVA
TCVA
HX
TCVA
•TIA
•TCVA
•ACS
* 1IA
•ACS
ACS
HX
•HX
ACS
•HX
ACS
•TCVA
•HX
•TIA
•TIA
•ACS
•ACS
•TCVA
TCVA
•HX
•TCVA
•TIA
•TCVA
•HX
•TCVA
•HX
•ACS
188
173IH
213
200
193
246
152IH
182
247
192
247
270
301
192
214
154
240
330
263
149
310
214
15HH
207
354RX
230
225IH
244
302
256
211
169IH
34
54IH
43
—
26
51
42IH
39
42
42
—
—
49
—
—
45
38
73
42
48
—
—
3HH
35
—
25
34IH
58
49
20
92
92IH
154
—
147
162
80IH
115
176
125
—
—
207
—
—
97
160
229
188
78
—
—
85IH
153
—
—
136IH
202
186
—
0.63
0.41
0.72
—
0.82
0.69
0.48
0.66
0.76
0.66
—
—
0.76
—
—
—
0.54
0.76
0.68
0.78
0.38
—
—
0.64
0.77
—
—
0.75
—
0.71
0.74
310
133IH
80
144
101
167
15HH
138
146
126
614
263
223
124
150
—
59
212
141
163
117
126
293
177IH
93
278RX
917
275IH
193
207
103
627
—
—
80
93
107
99
D
312RX
—
108
607
136D
112
78
93
D
125
114
88
125
91
108
416
—
107
90
388
—
94
299
—
past
past
past
263 38 196 0.81 146 133
pipe
past
past
past
past
past
past
past
past
past
past
past
+
past
128
94
130
142
160
124
148
210IH
128RX
160
128
118
162
166
154
154
156RX
150RX
140
130
186RX
132RX
168
110
130
160RX
104
12-2
168
180IH
130RX
160RX
128
174
126RX
188
148
144
78
66
76
100
98
56
92
100IH
60RX
82
80
78
90
104
94
84
76RX
88RX
70
72
42RX
82RX
88
88
82
86RX
48
80
106
100IH
70RX
92RX
72
78
60RX
100
102
76
27
15
19
22
22
31
26
—
21
28
25
29
31
26
33
28
29
—
25
27
23
24
26
—
27
24
30
26
37
—
32
34
23
29
27
28
—
29
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TABLE 7 (Continued)
Age
73
73t
74t
74
74
75t
76f
76f
78f
78
78
79t
79t
82f
84f
84f
85t
85t
86f
88f
89t
90t
Age
46f
47
52f
53
55t
58
6lf
63t
64f
64f
66f
ASBD
• H X
• H X
• TCVA
•ACS
HX
• H X
• H X
• H X
• H X
•ACS
• H X
ACS
ACS
HX
•TIA
• H X
TCVA
• H X
TIA
•TCVA
TIA
HX
ASVD
TAA
HX
•ASPVD
•AAA
•AAA
AAA
•AAA
•ASPVD
•ASPVD
ASPVD
• ASPVD
CT
212
168RX
264
184IH
141
236IH
242IH
257
271
270
114IH
202
—
—
280
173
240
200
—
248
283
161
CT
—
155
212
318
304
187
301
261
214
200
264
HDL
47
41RX
41
25IH
47
27IH
34IH
36
44
33
35IH
48
—
—
—
29
—
34
—
48
80
38
HDL
—
27
35
39
—
34
49
—
—
—
42
LDL
138
73RX
175
110IH
68
166IH
136IH
170
201
194
49IH
137
—
—
—
86
—
157
—
182
170
99
LDL
—
104
138
232
—
118
207
—
—
—
190
CRF
0.66
0.44
0.77
0.77
0.31
0.84
0.75
0.79
0.78
0.83
0.29
0.65
—
—
—
0.66
—
0.78
—
0.74
0.53
0.62
TG
137
270RX
241
244IH
130
214IH
360IH
256
130
216
151IH
87
—
—
196
290
150
47
—
91
166
120
TABLE 8
Male ASVD.
CRF
—
0.74
0.75
0.83
—
0.71
0.76
—
—
—
0.78
TG
—
119
197
235
360
174
223
105
150
212
160
PSL
102
—
140
D
155
—
—
161
—
266
D
84
—
—
342
123
102
—
—
146
100
—
PSL
—
—
—
95
181
—
112
115
93
66
103
Cigarettes
past
past
past
pipe
past
chews
+
past cigars
past
chews
-
-
+
-
past
cigars
past pipe
pipe
chews
-
-
-
Cigarettes
+
+
+
+
+
+
+
past
pipe
+
+
SBP
168RX
112RX
220
132
156
96
128RX
134
186
146
160RX
128
160IH
132
200
194
122
144
150
138
162
102
SBP
198RXIH
110
132RX
110
190
130
166
158
154
180
190
DBP
100RX
78RX
108
76
88
54
80RX
80
100
94
84RX
72
70IH
68
100
96
86
80
104
70
80
68
DBP
142RXIH
68
72RX
80
104
86
104
90
84
92
98
BMI
27
27
28
33
28
27
34
28
28
30
—
26
—
20
25
27
24
24
28
26
22
—
BMI
—
—
28
27
39
25
26
27
28
28
31
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TABLE 8 (Continued)
Age
67
6«t
68f
69t
69t
70
71
72t
73t
74f
75
75
76f
76t
77
78f
78
78f
79
80t
82f
82
83t
84
84f
84f
87t
88f
Age
39
41
42
44
45
ASBD
•AAA
•TAA
•ASPVD
•ASPVD
•ASPVD
•AAA
•AAA
•ASPVD
•ASPVD
•ASPVD
•ASPVD
•ASPVD
•AAA
• H X
HX
•AAA
•AAA
•ASPVD
• H X
ASPVD
•ASPVD
ASPVD
•ASPVD
•AAA
•AAA
•AAA
•ASPVD
•AAA
ASVD
HX
AP
AP
AP
AP
CT
207
356
230
173
—
354RX
243
214
163
126
241
211
252
257
—
256
270
263
178RX
206
302
222
19HH
117
173
229
232
248
C T
200
252
271RX
264
304
HDL
35
—
25
—
—
—
—
—
32
52
—
20
47
36
—
49
33
38
37RX
54
58
46
25IH
34
29
70
49
48
HDL
22
50
62RX
—
_
LDL
153
—
—
—
—
—
—
—
94
62
—
—
171
170
—
186
194
196
124RX
125
202
157
94IH
73
86
137
154
182
LDL
156
146
196RX
—
_
CRF
0.77
—
—
—
—
—
—
—
0.66
0.16
—
—
0.73
0.79
—
0.74
0.83
0.81
0.70
0.57
0.71
0.71
0.73
0.53
0.66
0.49
0.68
0.74
TG
93
278
917
93
—
278RX
225
293
183
61
172
627
169
256
—
103
216
146
86RX
134
207
96
362IH
52
290
108
146
91
TABLE 9
Female ASHD.
CRF
0.86
0.66
0.68
—
_
TG
138
281
66RX
72
94
PSL
107
225
388
162
—
90
87
416
326RX
89
119
—
198
161
__
—
266
133
—
171
299
__
—
91
123
79
79
146
PSL
119
—
97
70
498
Cigarettes
_
+
past
pipe
past
past
+
-
chews
+
chews
past
past
past cigars
+
+
-
past
past cigars
+
past
-
-
past cigars
cigars
past
past
-
Cigarettes
+
+
-
-
_
SBP
104
180
168
162RX
110
122
138
130
150RX
108
152
126RX
140
134
140
174
146
144
110RX
118
128
120RX
146
146
194
140
170
138
SBP
200
126
122
110
108
DBP
48
100
106
84RX
88
80
82
82
80RX
60
92
60RX
80
80
74
78
94
76
70RX
80
72
80RX
66
80
96
76
94
70
DBP
98
80
60
76
74
BMI
30
27
37
24
—
26
20
27
32
24
24
27
—
28
26
29
30
29
22
—
23
26
26
25
27
16
21
26
BMI
46
27
27
28
24
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TABLE 9 (Continued)
Age ASBD CT HDL LDL CRF TG PSL Cigarettes SBP DBP BMI
46
47
47
48
49
52
52
53t
53
54f
54
54
55
55
56
56t
56
56
57
57
57
57
58
58t
58
58
58
59
59t
59t
60
60
60
60
60f
60
60
61
6lt
AP
AP
HX
ACI
AP
+Treadmill
AP
•HX
•AP
HX
HX
AMI
HX
HX
HX
HX
CHF
HX
AP
AP
HX
AP
HX
AMI
AP
ACI
•CHF
AP
AMI
+Treadmill
AP
AP
AP
+Treadmill
AMI
AP
+Treadmill
AP
CHF
285
226
—
219
237
228
246
222
318
188
341IH
276
272
—
304
295
256
217
246
219
—
312
210
274
267
381
239
220
204
290
230
237
246
233
280
254
185RX
433
337
49
70
—
—
67
—
48
—
56
—
—
65
76
—
40
39
36
56
—
—
—
38
—
—
29
96
81
—
—
—
—
—
—
46
—
48
70RX
54
49
158
128
—
—
152
—
123
—
215
—
—
193
176
—
216
195
189
135
—
—
—
222
—
—
202
258
141
—
—
—
—
—
—
141
—
156
70RX
294
250
0.69
0.45
—
—
0.56
—
0.61
—
0.74
—
—
0.66
0.57
—
0.81
0.80
0.81
0.59
—
—
—
0.83
—
—
0.86
0.63
0.43
—
—
—
—
—
—
0.67
—
0.69
0.00
0.82
0.89
391
140
—
129
88
217
375
330
235
251
—
91
100
—
239
353
156
132
112
156
—
283
313
270
182
137
85
160
125
182
145
388
608
229
110
250
227RX
423
190
108
69
—
101
129
67
101
146D
140
166RX
—
—
55
—
153
383
100
106
130
86
—
—
136
1070
78
—
—
112
1150
167
59
102
214
93
142D
293
122
136
past
past
past
past
past
94
146
118
144
122RX
152
172
164
224
154
152RX
160
130
168RX
140
142RX
158
126
132
132
158RX
164
230
140
120
180
102
110
190
190
148
142
140
106
138
142RX
160RX
162
102RX
70
98
60
90
74RX
98
104
86
130
82
98RX
98
74
82RX
88
80RX
80
74
80
84
90RX
58
110
64
80
94
68
72
112
134
80
80
88
62
92
90RX
88RX
100
66RX
28
30
33
30
39
26
31
18
40
29
31
—
21
27
24
35
42
22
25
36
43
33
34
24
41
21
18
22
35
35
25
31
31
25
33
33
28
25
23
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Age
62
62
63
63+
63+
63t
63
63
63
64
64
64f
64
65+
66
66
67
68f
68
68
68
69t
69t
69
69+
69
69+
69
69
69
69
70+
70
70
70
70
70
71+
71+
ASBD
HX
•HX
HX
•HX
HX
AMI
•CHF
AP
•HX
AMI
HX
HX
HX
CHF
•HX
HX
AP
AMI
AP
HX
CHF
•CHF
HX
HX
•HX
+Treadmill
HX
AMI
AP
AP
AP
HX
•CHF
HX
AP
HX
HX
AMI
AMI
CT
235
265
186
308
144
273
292
175
—
208
—
—
—
295
242
276
229
318IH
217
158
481
171IH
259IH
179
263
319
—
—
294IH
298
182
238
284
—
218
324
177
240
286
HDL
—
55
—
—
—
—
68
33
—
45
—
—
—
51
55
36
46
34IH
34
30
43
39IH
63IH
27
33
50
—
—
44IH
38
—
—
32
—
93
57
32
—
LDL
—
185
—
—
—
—
208
97
—
151
—
—
—
186
177
206
137
194IH
136
102
362
107IH
176IH
83
161
215
—
—
209IH
166
—
—
203
—
99
218
94
—
_
CRF
—
0.70
—
—
—
—
0.67
0.67
—
0.70
—
—
—
0.73
0.69
0.83
0.66
0.82
0.75
0.71
0.88
0.64
0.64
0.67
0.80
0.77
—
—
0.79
0.77
—
—
0.84
—
0.06
0.74
0.66
—
_
TG
92
125
196
248
248
295
81
229
—
60
—
—
—
292
65
172
231
451IH
233
130
217
125IH
100IH
343
347
269
—
—
203IH
470
101
163
246
—
128
246
255
139
166
PSL
94
101
270RX
—
115
300
—
278RX
D
153D
D
—
—
—
—
106
108
D
124
278
78
D
—
157
417
192
—
—
84IH
134
95
86
128
—
107
82
146
87
126D
Cigarettes
-
+
-
+
past
-
+
-
past
-
-
+
+
+
past
-
-
-
past
-
-
-
past
past
+
-
+
+
-
-
-
+
-
-
-
-
-
-
_
SBP
150
172RX
118
136
154
158
112
128RX
90RX
150
92RX
118IH
100RX
118
118
160RX
176
144
122
192
168RX
186
124
158
150
158
152RXIH
88RX
130
120RX
110
138
186
156RX
152
148
128RX
178
184
DBP
86
98RX
78
90
104
86
70
80RX
60RX
74
54RX
70IH
62RX
78
78
80RX
84
96
62
80
90RX
104
86
94
76
72
90RXIF
68RX
80
82RX
70
82
114
96RX
94
80
80RX
90
90
BMI
26
25
28
27
39
28
16
41
21
25
25
—
19
22
22
29
29
25
31
31
43
25
24
35
33
22
I —
33
28
39
21
15
31
34
36
29
23
28
33
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TABLE 9 (Continued)
Age
71
71
72
72
72
73
73
73t
73
74f
74f
74f
74
74
74f
74
75t
75
75
75
75
75
76
76
76
76f
77
77
77
77
77f
77t
77
77
77f
78
78f
78
78
ASBD
HX
•AP
HX
HX
HX
•AP
•AP
•AMI
HX
CHF
AMI
AP
HX
AP
•AP
AMI
•AP
•HX
•HX
HX
AP
•HX
•CHF
HX
HX
AP
CHF
HX
AP
CHF
AMI
ACI
AMI
•CHF
AMI
HX
AMI
HX
AP
CT
219IH
247
196
190
244
152
304
216
—
277
—
216
274
218
351
268
293
187
144*
276
267IH
—
233
314
247
—
168IH
214
315
199
—
—
—
—
HDL
44IH
71
—
—
74
40
—
66
—
25
—
—
67
48
74
58
—
65
35*
—
44IH
—
—
90
62
—
35IH
58
—
42
—
—
—
—
LDL
145IH
146
—
—
144
76
—
114
—
—
—
—
184
142
213
184
—
104
102*
—
204IH
—
—
200
163
—
108IH
136
—
—
—
—
—
—
(CT ELEVATED, ON MEVACOR)
282
224
268IH
150IH
—
55
—
51IH
—
150
—
8IH
CRF
0.70
0.51
—
—
0.49
0.47
—
0.42
—
—
—
—
0.64
0.66
0.65
0.68
—
0.38
0.66
—
0.78
—
—
0.55
0.62
—
0.67
0.57
—
—
—
—
—
—
—
0.63
—
0.41
TG
148IH
150
202
81
128
179
213
178
_
787
—
145
117
138
321
132
162
88
41*
131
94IH
—
239
118
110
—
139IH
99
234
—
—
—
—
—
—
308
94
179IH
67TH
PSL
D
103
492
81
—
—
141D
117
D
492
—
240
92
134
109
—
103
78
101
52
—
D
118
94
78
D
D
—
I l l
—
D
—
—
106
D
116
184
—
Cigarettes
past
+
past
past
-
+
-
-
past
past
unkown
-
-
-
-
+
-
-
-
-
past
-
-
+
+
+
-
-
-
-
-
+
-
past
-
-
-
SBP
140
126
132
138
120
136
184
160
130
132
112
194
138
148
156
148RX
180
156
130
190
120
118
156
210
126
116
184RX
154RX
114
174
180RX
110
122
130RX
120RXIH
178
172RX
120RX
128
DBP
80
76
62
74
68
70
88
76
60
64
70
96
78
78
80
60RX
110
90
88
88
74
60
90
106
76
84
98RX
88RX
74
70
110RX
84
70
62RX
86RXIH
100
80RX
64RX
80
BMI
34
18
27
23
21
16
30
31
32
28
21
35
28
22
30
20
28
26
20
28
17
24
26
29
18
21
32
30
22
37
32
—
24
30
—
27
25
25
OHIO JOURNAL OF SCIENCE
TABLE 9 (Cont inued)
W. E. FEEMAN, JR. 175
Age
78f
78
78
78f
78
79t
79
80f
80f
80
81t
81
81
81
82f
82f
82f
82
83t
83
83
83
84
84f
84
85t
85t
85t
85
85t
86f
86
86f
86f
86f
87
88
89t
89
ASBD
HX
HX
AP
•CHF
AP
•CHF
•AMI
•CHF
CHF
•AP
•AP
•HX
AP
•HX
CHF
•CHF
•CHF
•CHF
AP
CHF
HX
HX
HX
CHF
AP
•CHF
HX
•CHF
HX
CHF
•HX
CHF
AMI
CHF
•AP
HX
•HX
•CHF
•CHF
265IH
247IH
232
252
220
—
290
230RXIH
190
321
206
—
321IH
212
286
228
368
205
266
—
158
—
250
218
211
256
227
320
239
—
244
246
—
167
315
263
—
218
241
HDL
52IH
60IH
72
82
36
—
41
—
—
48
—
—
112IH
56
—
—
56
48
51
—
52
—
48
87
46
—
71
63
52
—
—
42
—
57
58
51
—
105
62
LDL
168IH
168IH
132
154
132
—
201
—
—
235
—
—
177IH
138
—
—
261
142
154
—
93
—
169
113
115
—
133
227
149
—
—
171
—
97
222
171
—
101
142
CRF
0.69
0.64
0.45
0.47
0.73
—
0.80
—
—
0.80
—
—
0.37
0.59
—
—
0.79
0.66
0.67
—
0.44
—
0.72
0.23
0.60
—
0.47
0.72
0.65
—
—
0.75
—
0.41
0.74
0.70
—
-0.04
0.56
TG
225IH
94IH
139
82
262
—
238
194RXIH
130
192
182
—
159IH
89
155
174
255
92
307
—
65
—
166
90
249
218
116
151
188
—
105
166
—
63
175
258
—
59
184
PSL
D
—
136
63
300
D
101
144IH
—
79
—
D
—
120
89
H I D
D
162
109
—
—
—
97
—
—
222
154
121
—
—
122
—
—
97
174D
255
—
87
191
Cigarettes
-
-
-
-
past
-
past
past
-
-
-
-
past
past
-
-
-
-
-
-
past
past
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
SBP
184RX
164
144
174
118RX
148
190
168RX
188
134
198RX
130RX
124RX
138RX
176
160
178
148
170RX
152
156
164RX
190
122RX
132RX
142
180
160
168
160
140
160
184
112RX
182RX
168RX
158
104
176
DBP
86RX
74
86
100
68RX
82
88
108RX
110
66
94RX
80RX
64RX
80RX
102
70
66
90
92RX
88
82
102RX
100
74RX
74RX
84
104
68
90
74
72
80
142
64RX
72RX
80RX
80
60
102
BMI
36
22
28
24
26
26
23
—
23
23
30
28
30
35
24
21
38
28
30
19
30
24
30
19
19
33
21
29
28
15
24
22
22
—
23
26
—
20
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TABLE 9 (Continued)
Age ASBD HDL LDL CRF TG PSL Cigarettes SBP DBP BMI
89t
90f
90f
92t
92
96
• CHF
•CHF
CHF
CHF
•HX
CHF
227
262
232
51
97
63
135
138
149
0.62 204
0.30 134
0.58 98
287
95
past
158
144
124
156
124
122
80
66
82
72
82
76
37
20
—
20
—
24
TABLE 10
Female ASBD.
Age ASBD HDL LDL CRF TG PSL Cigarettes SBP DBP BMI
47
51
53
56f
62
62
63
64
65
66f
66
66
67t
68f
69
69t
71
73
73
74
74
75
75
75
76f
76
HX
HCVA
•TCVA
TCVA
HX
•HX
•HX
TCVA
TCVA
•TCVA
•TIA
•HX
•HX
HX
•TIA
•TCVA
TIA
•ACS
•ACS
•ACS
TCVA
•TIA
•HX
TCVA
• TCVA
•TIA
280
284
318
271
188
265
—
186
250
222
292
242
293
268
291
263
212
304
290
152
264
144
—
—
216
284
50
52
56
49
72
55
—
40
66
—
68
55
—
—
—
33
—
—
41
40
51
35
—
—
66
32
169
170
215
175
105
185
—
110
155
—
208
177
—
—
—
161
—
—
201
76
198
102
—
—
114
203
0.70
0.69
0.74
0.72
0.31
0.70
—
0.64
0.59
—
0.67
0.69
—
—
—
0.80
—
—
0.80
0.47
0.74
0.66
—
—
0.42
0.84
305
309
235
233
57
125
—
181
154
330
81
65
162
119
224
347
150
213
238
179
93
41
—
—
178
246
99
200
140
D
—
101
—
116
—
146
—
—
103
132
75
417
113
141
101
—
—
101
—
—
117
128
+
+
-
+
-
+
past
past
+
+
+
past
-
+
+
+
-
-
past
+
-
-
-
-
-
104
180
224
220
118
172RX
90RX
150RX
178
164
112
118
180
142RX
102
150
182IH
184
190
136
118RX
130
118
160
160
186
66
110
130
118
84
98RX
60RX
100RX
80
86
70
78
110
80RX
70
76
94IH
88
88
70
80RX
88
60
88
76
114
31
27
40
—
22
25
21
59
19
18
16
22
28
18
22
33
31IH
30
23
16
34
20
24
38
31
31
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Age
l6\
76t
77
77
77t
79
79
79t
79t
80f
81
81t
81
82t
82f
83t
83t
83t
85
85
86t
86f
87
88
88
91t
92f
92
94t
Age
55
58
66f
ASBD
•ACS
HCVA
•HX
•ACS
TCVA
TCVA
•HX
•HX
•TIA
HX
TIA
•HX
•HX
•TCVA
•HX
TIA
•TCVA
TIA
•TCVA
•TIA
•HX
•HX
•TCVA
TCVA
•HX
•TCVA
•TIA
•HX
•TCVA
ASVD
ASPVD
•ASPVD
•HX
CT
351
229IH
184
—
—
232
321
368
252
213IH
261
206
—
228
171IH
145
230
265
187
205
244
315
241
236
—
227
262
—
218
CT
352
239
222
HDL
74
46IH
39
—
—
—
48
56
82
39IH
—
—
—
—
39IH
41
—
67
65
48
—
58
62
70
—
51
97
—
105
HDL
44
81
_
LDL
213
146IH
113
—
—
—
235
261
154
132IH
—
—
—
—
107IH
87
—
189
104
142
—
222
142
150
—
135
138
—
101
LDL
273
141
_
CRF
0.65
0.68
0.65
—
—
—
0.80
0.79
0.47
0.70
—
—
—
—
0.64
0.53
—
0.65
0.38
0.66
—
0.74
0.56
0.53
—
0.62
0.30
—
0.04
TG
321
187IH
162
—
—
215
192
255
82
226IH
160
112
—
174
125IH
86
194
44
88
92
105
175
184
80
—
204
134
—
59
TABLE 11
Female ASVD.
CRF
0.84
0.43
TG
173
85
330
PSL
109
—
—
106
—
117
79
—
63
—
99
—
—
I l l
—
107
144
—
78
162
122
174
191
78
—
287
—
—
87
PSL
113
—
146D
Cigarettes
-
past
past
-
-
-
-
-
-
-
+
-
-
-
-
past
past
-
-
-
-
-
-
-
-
-
past
-
-
Cigarettes
+
+
+
SBP
156
170IH
144RX
130RX
138
134
134
178
174
120
174
198RX
130RX
160
186
170RX
168RX
190RX
156
148
140
182RX
176
154
158
158
144
124
104
SBP
128
102
164
DBP
80
86IH
80RX
62RX
74
80
66
66
100
60
78
94RX
80RX
70
104
120RX
108RX
90RX
90
90
72
72RX
102
76
80
80
66
82
60
DBP
60
68
86
BMI
30
—
22
30
—
33
23
38
24
—
26
30
28
21
25
29
—
—
26
28
24
23
—
25
—
27
20
—
20
BMI
15
18
18
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TABLE 11 (Continued)
Age
66
68
68f
70
74
78
79
80+
80
81
81
82
83
83
85t
85t
88f
89
89
92
92
ASBD
•ASPVD
• ASPVD
• AAA
•ASPVD
• HX
•ASPVD
•ASPVD
•ASPVD
AAA
•ASPVD
ASPVD
•ASPVD
•ASPVD
ASPVD
ASPVD
• ASPVD
•ASPVD
ASPVD
•ASPVD
•ASPVD
ASPVD
CT
242
296
308
233
144+
247
290
—
225
184
222
212
—
237
230
256
320
192
—
—
—
HDL
55
—
—
—
35+
71
41
—
30
39
63
56
—
60
—
—
63
36
—
—
—
LDL
177
—
—
—
102+
146
201
—
—
113
140
138
—
141
—
—
227
125
—
—
—
CRF
0.69
—
—
—
0.66
0.51
0.80
—
—
0.65
0.55
0.59
—
0.57
—
—
0.72
0.71
—
—
—
TG
65
224
248
239
41+
150
238
—
1030
162
93
89
—
180
144
218
151
156
—
—
—
PSL
75
72
118
101
103
101
—
350
—
—
120
—
136
115
222
121
116
—
—
—
Cigarettes
past
+
+
-
-
+
past
-
-
past
-
past
past
-
-
-
-
-
-
-
-
SBP
118
102
136
156
130
126
190
148
130RX
144RX
180
138RX
164RX
118RX
170
142
160
102
158
124
116
DBP
78
70
90
90
88
76
88
82
72RX
80RX
118
80RX
102RX
68RX
100
84
68
60
80
82
58
BMI
22
22
27
26
20
18
23
26
24
22
29
35
24
24
21
33
29
26
—
—
26
Descriptions of patients whose plots fell within the minimum risk
zone in Fig. la:
1) Plot 0.50 vs. 132 — This man is a 48 year-old treated hypertensive
diabetic, who has had chronic persistent hepatitis for the last 25
years. Whenever his liver decompensated, as it did frequently over
this time-frame, his lipids rose to very high levels. The CRF plot
utilized represents his lipids at a time when his liver was quiescent.
Had the author elected to use a CRF obtained when his liver had been
decompensated, the CRF would have been above the line. Moreover,
the SBP used was the value obtained on his first office visit, after his
BP had been treated. Had the author elected to disregard the study
guidelines and use a BP obtained prior to his entry into the study, the
untreated BP value would have been much higher and again the plot
would have been well above the line. He required coronary artery
bypass surgery, but since then has done well.
2) Plot 0.06 vs. 152 — This 70 year-old woman is 100 lbs overweight. Her
husband, a heavy cigarette smoker, died slowly over a two-year
period, and the stress of his slow demise from COPD and then from
lung cancer caused her to develop angina and congestive heart
failure. After he died, she adapted to his death, her symptoms
resolved, and she was taken off her medication. Since that time she
has not had any more ASD symptomatology and is not limited in her
activity except by a case of persistent bursitis. She is now 78 years
old. It is the opinion of the author that this woman does not have
ASHD, but rather her heart had no cardiac reserve with which to
respond to the catecholamine bombardment when she was under
tremendous stress, and so underwent decompensation. The lack of
cardiac reserve is directly attributed to her obesity.
3) Plot 0.29 vs. 160 — This 78 year-old man entered the BGS having
already been treated for hypertension. He had a history of ASHD.
4) Plot 0.49 vs. 120 — This 72 year-old woman entered the BGS with
a history that a few years earlier she had been ill in bed for about three
weeks. A heavy snow had fallen and the patient had gone out to
shovel her driveway. She had half finished her job when she
experienced severe pain and collapsed to the ground. When she was
capable of doing so, she crawled back into her house and went to
bed. An EKG done a few days later showed an old myocardial
infarction. She is now 78 years, and has recurrent chest pains,
relieved by nitroglycerin.
5) Plot 0.41 vs. 128 — This 78 year-old woman is bed-ridden post-
stroke and has an extremely labile emotional state. She also has
anginal symptoms, relieved by nitroglycerin. It appears that her
symptoms are at least in part the result of a coronary vasospasm.
6) Plot 0.45 vs. 144 — This 78 year-old woman has angina of effort,
relieved by nitroglycerin, which she uses time to time. She is now 83
years old and is doing well.
7) Plot 0.70 vs. 110 — This 79 year-old man was presented to the BGS
with an acute myocardial infarction and rupture of the
myocardium posteriorly. He survived on conservative treatment.
In 1976 he suffered, at age 59 years, an aortic aneurysm. At that
time his cholesterol was 276 mg/dl. He subsequently went
on a low cholesterol diet. His blood pressure was maintained at
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100-110 niinHG systolic by medication as part of the therapy of his
myocardial pseudoaneurysm.
8) Plot 0.56 vs. 122 — This 49 year-old woman was diagnosed by
another physician as having angina pectoris. The author interviewed
the former patient and concurred with her current physician's
diagnosis. However, no treadmill test was done to confirm the
diagnosis. She is now a hypertensive diabetic, but the plot represents
the data when she first presented to the BGS.
9) Plot 0.00 vs. 160 — This 60 year-old woman developed typical chest
pain. A treadmill test was positive, though a thallium study was
normal. Consultation with a cardiologist indicated that the treadmill
results strongly warranted an angiogram, which to date has not been
done because the patient, who feels well, is unwilling. Her lipid data
were obtained at BGS presentation when she was already on
hormone replacement therapy, which is known to influence lipids.
Her high blood pressure was already being treated at BGS presentation.
10) Plot 0.31 vs. 118 — This 62 year-old lady had a CAT scan for
headaches and was found to have had two strokes, neither of which
she nor the author had been aware. The old cerebral infarcts were
incidental findings. Historical investigation revealed that both her
mother and her maternal grandmother had suffered strokes. To date,
detailed investigation, under the supervision of a neurologist, has
failed to reveal a cause. The patient has Parkinson's disease and takes
multiple medications for this condition. Her lipid data was obtained
while she was on these medications.
In the first 16 years of the BGS, these are the only known exceptions
below the line. The ASD of these individuals is relatively mild. All are still
alive, some now in their eighties.
APPENDIX III
The medical research literature upon which the BGS is based
supports the use of the CRF as the optimal lipid predictor. There are now
six major epidemiological studies and nine angiographic studies that
provide a basis for this statement. A brief description of each of these
studies is now presented.
1) Lipid Research Clinics Program (LRC): The LRC studied 3,806 men
with Type II Hyperlipoproteinemia. The lowest CT entry was 265 mg/
dl. This was a primary prevention trial. Using Questran™, patients
lowered their CT by 13.4% and LDL by 20.3% . The average LDL prior
to therapy, which also included a low cholesterol and saturated fat
diet, was 216 mg/dl. With therapy the average LDL fell to 175 nig/
dl, the average HDL rose to 47 mg/dl, and the average CRF fell to
73%. As a result of this therapy, the treated group subsequently
suffered 30% fewer definite and suspect cardiac deaths and 15%
fewer definite and suspected non-fatal heart attacks. Of interest is the
fact that this benefit was not evident until the third year of the study
(Lipid Research Clinics 1984).
2) Helsinki Heart Study (HHS): The HHS examined 4,081 men with
dyslipidemia using its entrance criterion a "non-HDL" cholesterol of
199 mg/dl. This was also a primary prevention trial. The HHS used
Lopid™, which lowers LDL but also raises HDL, in the treatment arm
of the study. Both treatment and placebo groups were placed on a
low cholesterol and low saturated fat diet, were advised to exercise
and lose weight, and were told to stop smoking. The treatment group
lowered its average LDL from 189 mg/dl to 174 mg/dl at the end of
the treatment five years later; HDL had risen from 47 mg/dl to 51 mg/
dl; CRF had fallen from 75% to 71%. Over the study period the
treatment group had a 34% drop in subsequent ASD, primarily in
non-fatal myocardial infarctions. The cardiac ASD fatality rate was
5.3 per thousand in the treatment group versus 6.4 per thousand in
the placebo group. As in the LRC, no benefit was seen until the third
year of the study (Frick et al. 1987).
3) National Heart, Lung, and Blood Institute Type II Coronary
Intervention Study: Kelsey discussed this trial which was an attempt
to reverse angiographically documented ASHD by diet and medication.
This therapy dropped mean LDL levels from 242 mg/dl to 178 mg/
dl and raised mean HDL levels from 38 mg/dl to 41 mg/dl. The
average CRF fell from 84% to 77%. The control group was treated
only with diet. The control group's plaques progressed in 49% of
cases, whereas progression was noted in only 32% of the treated
patients. Regression, both probable and definite, occurred in only
four of the treated patients and did not differ from the control group
(Kelsey 1986). Levy, who conducted the study, comments as follows:
"Using coronary angiography, there is evidence that an increase in
HDL, a decrease in LDL, or preferably both, could delay or prevent
coronary artery disease progression." Levy further noted that the
least progression and some regression of angiographically documented
ASHD occurs in groups showing the most decrease in LDL and the
most increase in HDL (Kelsey 1986).
4) E. A. Nikkila: Nikkila studied patients with ASFID, treating them with
diet and medication. Serial angiograms were done. No cases of lesion
regression were seen, but those who did not show progression
brought their LDL levels down to 159 mg/dl and their HDL levels up
to 45 mg/dl; those with slight progression brought their LDL levels
down to 173 mg/dl and their HDL levels up to 45 mg/dl; those
showing severe progression had LDL levels of 185 mg/dl and HDL
levels of 38 mg/dl. Respective CRFs were 72%, 74%, and 79% (Nikkila
et al. 1984).
5) D. H. Blankenhorn: Blankenhorn studied patients with progressive
ASHD. Treated patients were put on a stringent diet and medication
(niacin and Colestipol™), whereas the control group was put on a
less stringent diet. Treated patients dropped their LDLs from 170 mg/
dl to 97 mg/dl and raised their HDLs from 45 mg/dl to 6l mg/dl. The
CRF dropped from 74% to 37%. The control group dropped its LDL
levels from 169 mg/dl to 160 mg/dl, but was not able to raise their
HDL from the 44 mg/dl level; their CRF dropped minimally from 74%
to 73%- On repeat angiogram, the treated group had less ASD than
did the control group. Treatment produced a significant reduction in
progression of ASD in native coronary arteries, both in average
number of lesions that progressed per patient and in percentage of
patients with new plaque formation. Treatment also significantly
reduced the percentage of patients with any adverse change or
new lesion in venous bypass grafts. Blankenhorn concluded: "The
Cholesterol Lowering Atherosclerosis Study has demonstrated
that aggressive lowering of LDL cholesterol with concomitant
increase of HDL cholesterol levels produced significant benefit to
both native coronary arteries and venous bypass grafts"
(Blankenhorn et al. 1987).
6) L. Campeau: Campeau studied patients who had already had
coronary artery bypass graft surgery. He defined two groups of
patients based upon serial angiograms; one in which recognizable
abnormalities did not occur in by-passed arteries or in vein by-pass
grafts (Group I) and the other in which such abnormalities did occur
(Group II). Treatment was nonpharmacologic. Group I patients had
a drop in their LDL levels to 153 mg/dl and a rise in their HDL levels
to 63 mg/dl, whereas Group II patients maintained an LDL level of
190 mg/dl and an HDL of 48 mg/dl. Respective CRF values were 59%
and 75% (Campeau et al. 1984).
7) B. Lewis: Lewis studied ASD of the peripheral arteries (ASPVD) in
patients aged less than 65 years. Treatment was by diet and
medication, as well as advice to stop smoking. Control patients were
treated by diet and smoking advice. Treatment groups resulted in a
drop in LDL to levels of 151 mg/dl, a rise in HDL to levels of 58 mg/
dl, and a drop in CRF to 62%. Controls dropped their LDLs only to
197 mg/dl, raised their HDLs only to 42 mg/dl, and dropped their
CRFs only to 79%. Upon repeat angiography, treated patients
showed one third the increase in plaque areas showed by control
patients. Furthermore, twice as many treated patients showed a
decrease in their edge-irregularity index as did controls. Finally,
almost three times as many controls showed progression as did
treated patients (Lewis 1985 ).
8) R. G. M. Duffield: Duffield studied patients with ASPVD. All patients
were told to stop smoking and lose weight. Treated patients were
also given a special diet and medication. Treatment groups lowered
their LDLs from 209 mg/dl to 151 mg/dl and raised their HDLs from
47 mg/dl to 60 mg/dl. The CRF fell from 78% to 60%. Upon follow-
up angiogram, 33% of treated patients showed a decrease in
plaque edge-irregularity versus 17% of controls . Only 6.9% of
treated patients showed progression versus 17.3% of controls
(Duffield et al. 1983).
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9) G. Brown: Brown studied 146 men with a family history of ASHD, Apo-
B levels of 125 mg/dl or higher, and established ASHD (a single 50%
lesion or three 30% lesions on angiograms). Three treatment
regimens were given: placebo/Colestid™, Mevacor™/Colestid™,
and niacin/Colestid™ (Groups 3, 2, and 1 respectively) . Group 3
patients lowered their LDL levels from 4.53 mmoles/L to 4.2 mmoles/
L (176 mg/dl to 163 mg/dl), raised their HDL levels from 0.98
mmoles/L to 1.04 mmoles/L (38 mg/dl to 40 mg/dl) and lowered their
CRF from 0.78 to 0.75. Group 2 patients lowered their LDL levels from
5.08 mmoles/L to 2.77 mmoles/L (198 mg/dl to 108 mg/dl), raised
HDL levels from 0.91 mmoles/L to 1.06 mmoles/L (35 mg/dl to 41
mg/dl), lowered their CRFs from 0.82 to 0.62. Group 3 patients
lowered their LDL levels from 4.92 mmoles/L to 3-34 mmoles/L (191
mg/dl to 130 mg/dl), raised their HDL levels from 1.01 mmoles/L to
1.42 mmoles/L (39 mg/dl to 55 mg/dl) and lowered their CRF from
0.79 to 0.57. Serial coronary angiograms were done . After 2.5 years
of therapy, regression occurred in both Groups 2 and 1, (but
regression was always more pronounced in Group 1) whereas
Group 3 patients had consistently worsening stenosis (See table
below) (Brown et al. 1990).
Angiographic
1) regression
2) progression
GROUP 3
ASHD events (SUD, AMI, CABGS)
11%
46%
19%
GROUP 2
32%
21%
6.5%
GROUP 1
39%
25%
4.2%
(SUD = sudden unexpected death, AMI = acute myocardial infarction,
CABGS = coronary artery bypass surgery).
10) H. Buchwald: Buchwald studied 838 male survivors of AMI. Surgical
treatment (partial ileal bypass ) was done in 421 patients and 417
patients were put into the control group. All patients were treated
with diet therapy. The surgical group lowered its LDL levels from 4.62
mmoles/L to 2.82 mmoles/L (180 mg/dl to 110 mg/dl), raised their
HDL levels from 1.03 mmoles/L to 1.06 mmoles/L (40 mg/dl to 41
mg/dl), and lowered their CRF from 0.78 to 0.63- The control group
lowered their HDL levels from 1.05 mmoles/L to 1.00 mmole/L (41
mg/dl to 39 mg/dl) and did not change their CRF (0.77). AMI and
ASHD deaths did not differ between the two groups until the third
year, whereupon the surgical group began having fewer end points
then did the control group. When all ASHD events were combined,
222 events occurred in the control group versus 160 events in the
surgical group (P .00001) (Buchwald et al. 1990).
11) I. Hjerman: The Oslo Study Diet and Anti-Smoking Trial study
involved 1,232 healthy men aged 40-49 years, who had a CT in range
of 280-380 mg/dl. All were normotensive and 80% were cigarette
smokers. The treatment group received dietary advice and were
advised to stop smoking. The control group received no treatment,
however, 17% of controls stopped smoking, compared with 24% in
the intervention group. The treatment group lowered their LDL from
262 to 187 mg/dl, raised their HDL from 28 to 50 mg/dl, and lowered
their CT from 0.89 to 0.73- The control group did not lower their LDLs
(259 mg/dl), but did raise their HDL from 29 to 42 mg/dl, thus
lowering their CRF from 0.89 to 0.84. Coincident with these changes,
the treatment group had a reduction in cardiac deaths, 6.6 per
thousand vs 20.1 per thousand in controls. There was no difference
in AMI or CVA (Hjerman et al. 1986 ).
12) G. F. Neitzel: Neitzel studied patients who had undergone coronary
artery bypass surgery and who required a second operation (40
patients) versus 535 patients who did not require a second operation.
Those requiring a second operation had an average HDL of 38 mg/
dl, an average LDL of 175 mg/dl, and an average CRF of 0.78. Those
not requiring a second operation had an average HDL of 47 mg/dl,
an average LDL of 150 mg/dl and an average CRF of 0.69 (Neitzel et
al. 1986).
13) G. Schuler: Schuler studied men with stable angina, LDLs less than
210 mg/dl, and ASD not severe enough to prevent exercise therapy.
The treatment group received a low fat, low cholesterol diet and a
regular exercise program. The treated patients lowered their LDLs
from 147 mg/dl to 130 mg/dl, raised their HDLs from 39 mg/dl to 40
mg/dl, and lowered their CRFs from 0.73 to 0.69. The control group
had a rise in LDL from 150 to 172 mg/dl, a rise in HDL from 36 to 37
mg/dl, and a rise in CRF from 0.76 to 0.78. During the study two
control patients had an AMI versus no treated patients. Treated
patients had decreased myocardial ischemia on Thallium treadmill
with respect to controls at one year. This implies increased myocardial
perfusion in the patients with symptomatic ASHD. Physical work
capacity likewise increased in treated patients, but in no control
patients (Schuler et al. 1988).
14) G. Watts: Watts studied 90 men with angina or other findings of
ASHD and with C.r exceeding 231 mg/dl but TG less than 355 mg/
dl. The control group received the usual care; Group I patients
received diet counseling, whereas Group II patients had diet
counseling plus cholestyramine 8 g twice a day. The control group
had a minimal change in LDL (186 mg/dl to 180 mg/dl) and no
change in HDL (constant at 47 mg/dl). Group I patients lowered their
LDL (193 mg/dl to 161 mg/dl) but HDL remained unchanged at 44
mg/dl. Group II patients lowered their LDL (203 mg/dl to 130 mg/
dl) but also lowered their HDL (48 mg/dl to 46 mg/dl). Changes in
CRF were respectively 0.75 to 0.74 (controls), 0.77 to 0.73 (Group I),
and 0.76 to 0.65.(Group II). Follow-up was done by paired angiograms
and clinical event determination over a follow-up time averaging 39
months. All angiographic criteria consistently worsened in the
controls and consistently improved in Groups I and II, with all
segments in these latter groups showing improvements including the
most severe stenosis (See table below) (Watts et al. 1992).
CONTROLS GROUP I GROUP II
Sudden Unexpected Death 3 1 0
Acute Myocardial Infarction 2 1 1
Coronary Artery Bypass Surgery 4 1 0
Stroke 1 0 0
Total 10 3 1
(36%) (11%) (4%)
15) M. Fox: Fox studied ASD risk factors in patients who underwent
coronary artery bypass surgery. He compared those who required a
second operation at least six months later (Group I) vs. those who
did not require a second operation (Group II). Group I patients had
an LDL of 179 mg/dl, HDL of 49 mg/dl, and a CRF of 0.77, whereas
Group II patients had an LDL of 172 mg/dl, HDL of 44 mg/dl, and
a CRF of 0.74. More Group II patients were hypertensive (30.4% in
Group II vs. 21% in Group I) (Fox et al. 1992).
APPENDIX IV
LDL Medications
1) Bile acid resins [Questran™ and Colestid™]: These agents bind
cholesterol and bile acid within the gut, inhibiting cholesterol
absorption and interrupting the enterohepatic circulation of the bile
acids. When levels of bile acid fall, LDL receptors are induced within
the hepatocytes, removing LDL from the blood to be used in bile acid
synthesis (Shepherd et al. 1980). At doses of 4 g or more four times
a day, these agents are very effective in lowering blood cholesterol
(LDL), but also cause gastrointestinal distress with cramping, bloating,
and constipation. Such effects may occur even at lower doses,
especially in older individuals. The BGS therefore uses these resins
only in lower dosages, often as adjuncts to other medications.
Metamucil™ may be added to or substituted for the resins to reduce
side-effects.
2) Nicotinic acid [Nicobid™, etc.]: This drug decreases the hepatic
secretion of VLDL, thus lowering LDL and VLDL while raising HDL
by another mechanism (Shepherd et al. 1979). At therapeutic doses,
nicotinic acid causes flushing and itching. These sequelae can be
averted or at least minimized by taking the drug in sustained release
form, by taking the drug after meals, and by taking an aspirin with
each nicotinic acid dose. Unfortunately, at doses of nicotinic acid
required to achieve therapeutic goals—i.e., in the BGS experience,
Nicobid™ 1.0-1.5 g twice a day—there is a fairly high risk of drug-
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induced hepatitis and, in recent years after a number of such cases,
nicotinic acid is no longer prescribed at such a dosage. In addition,
the brand name is costly and if six capsules twice a day are used, the
cost per month could be excessive. As a result, reliance is placed
upon generic versions of the drug. This reduces the cost, but the
treating physician must be prepared for the occasional batch of drug
which appears to contain little if any active drug, as evidenced by
the observation that increasing the dose of nicotinic acid sometimes
results in rising LDL levels and falling HDL levels—just the opposite
effect that would be expected.
3) Probucol [Lorelco™]: This drug enhances the catabolism of LDL and
does so even in patients who do not possess LDL receptors in the
liver, This means that probucol can act directly in the liver by
inducing LDL receptors as blood levels of LDL fall or directly in the
periphery by "alternative pathways" independently of any hepatic
mechanism. The exact mechanism remains to be elucidated, but
may involve the reticuloendothelial system and its macrophages
(Steinberg 1986). BGS experience with probucol is limited to a
few patients since marked drops in HDL levels occur with
probucol administration. Although probucol may prevent the
progression of ASD in rabbits (Kita et al. 1987), the lowering of
HDL invalidates the use of CRF as predictive and therapeutic tool
and limits its use in the BGS.
4) Hydroxymethylglutaryl coenzyme A reductase inhibitors [lovastatin,
Mevacor™]: This drug interferes with conversion of
hydroxymethylglutaryl coenzyme A to mevalonate, an early rate-
limiting step in the synthesis of cholesterol (Havel et al. 1987). By
inhibiting cholesterol synthesis in hepatocytes, hepatic LDL receptors
are induced, internalizing circulating LDL for the synthesis of
hepatocyte intracellular cholesterol. This results in a marked drop in
blood levels of LDL and as an added benefit, HDL levels rise. At
doses of 20-40 mg of lovastatin per day, after supper, few adverse
sequelae have been noted from this drug after more than three years
experience, except for the cost, which is significant. The cost of
multi-drug regimens which may be necessary if lovastatin is not
used, however, often significantly exceeds the expense of lovastatin.
In the BGS, the preferred regimen is lovastatin 20 mg after supper
with/without 4 g of bile acid resin at bedtime. This regimen has
induced 100 mg drops in LDL levels in a convenient regimen which
is not too expensive.
5) Female hormone replacement therapy (HRT): HRT in the BGS is
defined as Premarin™ 1.25 mg daily for the first 25 days of each
month, complemented by Provera™/Cycrin™ 5-10 mg daily from
day 13-25- (The dose of Provera™/ Cycrin™ is usually 10 mg, but in
women who have had hysterectomies, may be reduced to 5 mg if
the occasion requires). HRT finds its use in peri- and postmenopausal
women as a physiological treatment for hyperlipidemia of the
menopause (Hirvonen et al. 1981). Following the suggestion of
Tikkanen, the BGS began using HRT as primary and adjunctive
therapy for the menopausal women (Tikkanen et al. 1978). The
results have been most gratifying. HRT is considered the treatment
of choice in appropriate patients.
HDL Medications
1) Nicotinic acid: Please see previous discussion.
2) Gemfibrozil [Lopid™]: This drug decreases hepatic secretion of
VLDL and increases VLDL catabolism (Vega and Grundy 1985). As
a result gemfibrozil lowers TG, has a variable effect of LDL, and
usually raises HDL. Because of these beneficial effects, the BGS has
utilized this drug extensively to raise low levels of HDL. In the BGS
experience, gemfibrozil has had a few adverse reactions, and so, if
the cheaper nicotinic acid fails to normalize HDL, the BGS does not
hesitate to switch to gemfibrozil.
3) Hydroxymethylglutaryl coenzyme A reductase inhibitors: This drug
may be used in HDL disorders only if other means of raising HDL
have failed. In such cases, the BGS policy is to abandon the failed
HDL regimen and to lower the LDL as simply and easily as possible
such that the CRF is low despite the low HDL. It is hoped that this
regimen will push back the onset of ASD by lowering the incoming
cholesterol until other HDL drugs are available.
TABLE 12
Dyslipidemia Medications.
I. LDL MEDICATIONS
A. Bile acid resins (Questran™, Colestid™, Metamucil™)
B. Nicotinic acid (Nicobid™)
C. Probucol (Lorelco™)
D. Lovastatin (Mevacor™)
E. Hormone Replacement Therapy (HRT)
II. HDL MEDICATIONS
A. Nicotinic acid (Nicobid™)
B. Gemfibrozil (Lopid™)
C. Lovastatin (Mevacor™)
